Medicinal Products

ECOBEC 250 μg / dose Inhalation oral pressurized bottle of 200 doses

Generic drug of the therapeutic class: Pneumology
active ingredients: Beclometasone
laboratory: Teva Sante

Solution for oral inhalation
All forms

Indication

- Continuous anti-inflammatory treatment of persistent asthma.
- Persistent asthma is defined as multi-weekly diurnal symptoms and / or nocturnal symptoms more than twice a month.
- Note: this device is particularly suitable for subjects who have been shown to have poor hand / lung synchronization necessary for proper use of conventional metered dose inhalers without an inhalation chamber.

Dosage ECOBEC 250 μg / dose Inhalation oral pressurized bottle of 200 doses

- Continuous anti-inflammatory treatment of persistent asthma.
- Persistent asthma is defined as multi-weekly diurnal symptoms and / or nocturnal symptoms more than twice a month.
- Note: this device is particularly suitable for subjects who have been shown to have poor hand / lung synchronization necessary for proper use of conventional metered dose inhalers without an inhalation chamber.

Against indications

Intolerance to this medication (occurrence of cough or bronchospasm after inhalation of the product). In this case it will be necessary to interrupt this treatment and to prescribe other therapies or other forms of administration.

Ecobec side effects

Local effects

· Possibility of oropharyngeal candidiasis. It usually gives way spontaneously or to appropriate treatment and it is exceptional that it requires the discontinuation of inhaled corticosteroid therapy. Its risk of appearance increases with the dose used and the number of shots. It can be prevented by rinsing the mouth with water after inhalation;

· Possibility of occurrence of pharyngeal discomfort, dysphonia, raucousness of the way, which can be prevented by rinsing the mouth after inhalation of the product;

· As with other inhaled products, possibility of coughing and rarely bronchospasm following inhalation. In this case, treatment should be discontinued and other therapies or other forms of administration prescribed.

Systemic effects

· Systemic effects may occur during long-term treatment with high doses (see section 4.4).

· Inhalant corticosteroids have been described with observations of cutaneous thinning, subcutaneous hematomas, depression of adrenal biological functions (decreased plasma cortisol and 24-hour cortisoluria) and bone scarcity.

The clinical consequences of long-term administration, particularly on bone tissue and growth, are not clearly established.

The administration of large doses in the long term may therefore require monitoring especially in children and the elderly.

In the current state of knowledge, although the search for the minimum effective dosage is always recommended, the risk to consider as a priority is that of insufficient control of asthma and should always be weighed against that of systemic impact.

· Very rare frequency: cataract and glaucoma.

· Psychiatric disorders:

Frequency not known: psychomotor hyperactivity, sleep disorders, anxiety, depressive syndrome, aggressiveness, behavioral disorders (mainly observed in children).

Popular Posts

Category Medicinal Products, Next Article